![Tassos Gianakakos](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Tassos Gianakakos
Algemeen Directeur bij
Prolaio, Inc.
Vermogen: 139 M $ op 31-10-2026
Profiel
Momenteel bekleedt Anastasios E. Gianakakos de functie van Chief Executive Officer voor MyoKardia, Inc. Hij zit ook in de raad van bestuur van LianBio. In het verleden was de heer Gianakakos President & Senior VP-Business Development bij Codexis, Inc., Procesingenieur bij Merck & Co, Inc., Directeur -Business Development bij Maxygen, Inc. en Chief Business Officer & Senior Vice President bij MAP Pharmaceuticals LLC. Hij behaalde zijn doctoraal aan het Massachusetts Institute of Technology, zijn doctoraal aan de Northwestern University en zijn MBA aan de Harvard Business School.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
10,49% | 30-06-2026 | 9.806.633 ( 10,49% ) | 139 M $ | 31-10-2026 |
LIANBIO 0,35% | 15-02-2024 | 363.253 ( 0,35% ) | 16 128 $ | 31-10-2026 |
Actieve functies van Tassos Gianakakos
| Bedrijven | Functie | Begin |
|---|---|---|
Prolaio, Inc.
 Prolaio, Inc. Packaged SoftwareTechnology Services Operates as a patient-centered clinical intelligence company | Algemeen Directeur | 01-11-2021 |
Eerdere bekende functies van Tassos Gianakakos
| Bedrijven | Functie | Einde |
|---|---|---|
| LIANMEDICAL | Directeur/Bestuurslid | 01-03-2024 |
| MYOKARDIA, INC. | Algemeen Directeur | 01-11-2020 |
MAP Pharmaceuticals LLC
 MAP Pharmaceuticals LLC Medical SpecialtiesHealth Technology Develops therapies and inhalation delivery technologies | Corporate Officer/Principal | 01-03-2013 |
| MERCK & CO., INC. | Hoofd Techniek/Wetenschap/O&O | 01-01-1997 |
Maxygen, Inc.
 Maxygen, Inc. Miscellaneous Commercial ServicesCommercial Services Develops directed molecular evolution technology | Corporate Officer/Principal | - |
Opleiding van Tassos Gianakakos
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
65
Eerstegraads connecties
10
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 10 |
|---|---|
Merck & Co., Inc.
 Merck & Co., Inc. Pharmaceuticals: MajorHealth Technology Manufactures human and animal health pharmaceutical products & vaccines | Health Technology |
Maxygen, Inc.
Maxygen, Inc. Miscellaneous Commercial ServicesCommercial Services Develops directed molecular evolution technology | Commercial Services |
Codexis, Inc.
 Codexis, Inc. Chemicals: SpecialtyProcess Industries Develops biocatalytic chemical processes | Process Industries |
MAP Pharmaceuticals LLC
MAP Pharmaceuticals LLC Medical SpecialtiesHealth Technology Develops therapies and inhalation delivery technologies | Health Technology |
MyoKardia, Inc.
 MyoKardia, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that discovers, develops and commercializes therapies for the treatment of cardiovascular diseases | Health Technology |
Massachusetts Institute of Technology
 Massachusetts Institute of Technology Finance/Rental/LeasingFinance Functions as a College/University | Finance |
Northwestern University
 Northwestern University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Harvard Business School
 Harvard Business School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
LianBio
 LianBio BiotechnologyHealth Technology Operates as a biotechnology company focused on bringing paradigm-shifting medicines to patients | Health Technology |
Prolaio, Inc.
Prolaio, Inc. Packaged SoftwareTechnology Services Operates as a patient-centered clinical intelligence company | Technology Services |
